I The vascular bed of the submandibular gland in situ was perfused with blood through the glandular artery at a constant pressure in anaesthetized dogs. All drugs were administered intra-arterially. 2 Vasoactive intestinal peptide (VIP), secretin and acetylcholine produced a dose-dependent increase in blood flow through the artery (vasodilatation) but glucagon was almost ineffective. 3 Dose-blood flow response curves for VIP and secretin were parallel, and VIP was about 100 times as potent as secretin on a molar basis. Dose-blood flow response curves for acetylcholine were flatter than those for VIP and secretin. Acetylcholine was approximately as potent as secretin on a molar basis. 4 No tachyphylaxis developed to the vasodilator action of VIP. 5 The vasodilator responses to VIP and to electrical stimulation of the chordolingual nerve were scarcely modified by (-Y)hyoscyamine in doses that fully antagonized the vasodilator response to acetylcholine. 6 VIP, secretin and glucagon were ineffective in eliciting salivary secretion. 7 The possibility that VIP is released from parasympathetic vasodilator nerves and mediates the atropine-resistant vasodilatation in the dog submandibular gland is discussed.
Introduction
Vasoactive intestinal peptide (VIP) isolated by Said & Mutt (1970; from the hog small intestine is now widely investigated because of its very potent biological activities (Said & Mutt, 1970; and its presence not only in endocrine cells in the gastrointestinal tract (Polak, Pearse, Garaud & Bloom, 1974; Bryant, Bloom, Polak, Albuquerque, Modlin & Pearse, 1976) but also in neurones in the autonomic and central nervous system (Bryant et al., 1976; Said & Rosenberg, 1976) . The presence of VIP in neurones led to the supposition that VIP may play a physiological role as a neurotransmitter or a neuromodulator (Bryant et al., 1976) . Indeed, Schaffalitzky de Muckadell, Fahrenkrug & Holst (1977) demonstrated the release of VIP upon electrical stimulation of the vagus nerve in anaesthetized hogs and suggested that VIP is possibly involved in the atropine-resistant pancreatic vasodilatation and exocrine secretion produced by vagal nerve stimulation in hogs.
The atropine-resistance of vasodilatation of the salivary gland produced by electrical stimulation of the chordolingual nerve is a century-old problem (Heidenhain, 1872) . The vasodilatation of the tongue 0007-1188/79/040683-05 $01.00 produced by chordolingual nerve stimulation is also atropine-resistant (Erici & Uvnas, 1952; Hilton & Lewis, 1958) . Although attempts to interpret the atropine-resistance by a special cholinoceptive mechanism (Dale & Gaddum, 1930; Schachter, 1967) have been made, other possibilities have also been sought. These include the involvement of the kallikrein-kinin system (Hilton & Lewis, 1955; 1958) and the suggestion of the possible release of novel transmitters (Taira, Narimatsu & Satoh, 1975; Shimizu & Taira, 1978) . Studies on the salivary gland (Ferreira & Smaje, 1976 ) and the tongue (Shimizu & Taira, 1978) of the dog using bradykinin-potentiating substances ruled out the possible involvement of the kallikrein-kinin system. Bryant et al. (1976) have demonstrated that in rats, hogs and man, nerve fibres in the salivary glands contain high concentrations of VIP. This tempted us to speculate that VIP might be responsible for the parasympathetically induced atropine-resistant vasodilatation there. In this respect it was of interest to investigate how potent VIP is in producing vasodilatation in the dog salivary gland and whether tachyphylaxis develops to its vasodilator action. VIP has been shown to be very potent in producing vasodilatation or hypotension (Said & Mutt, 1970) . Since VIP has been found to have an amino acid sequence related to that of secretin and glucagon (Mutt & Said, 1974) Effects of VIP, secretin, glucagon and acetylcholine on blood flow through and salivary secretion of the submandibular gland VIP was given to 5 and secretin to 6 of the 16 glands, and glucagon to the remaining 5 glands. Acetylcholine was given to all 16 glands. Single injections of VIP (0.3 to 100 pmol), secretin (0.1 to 10 nmol) and acetylcholine (0.1 to 30 nmol) into the glandular artery produced a dose-dependent increase in blood flow. A near maximum increase in blood flow was produced by 100 pmol of VIP or 10 nmol of secretin. However, glucagon even in a dose as large as 30 nmol produced only a slight increase in blood flow, although the glandular vascular bed of the S glands responded to acetylcholine in the same way as the remaining 11 glands. Typical experiments are shown in Figure 1 and dose-response curves for peak increase in blood flow to the three polypeptides are shown in Figure 2 , and dose-blood flow response curves for acetylcholine in Figure 3 . The dose-blood flow response curves for VIP and secretin were parallel, and VIP was about 100 times as potent as secretin on a molar basis. The dose-blood flow re- sponse curve to acetylcholine was flatter than that to VIP or secretin. Secretin was approximately equipotent to acetylcholine. The three polypeptides were almost ineffective in eliciting salivary secretion. Acetylcholine produced salivary secretion.
The second dose-blood flow response curves to VIP obtained in two glands in the absence of (-)-hyoscyamine appeared similar to the first curves, suggesting that there is no tachyphylaxis to its action. This was substantiated by the experiments described in the following section.
Absence of modification of blood flow responses to VIP by (-)hyoscyamine
The experiments were done on the same 5 glands that received VIP. Single injections of acetylcholine (0.1 to 30 nmol) produced an increase in blood flow and salivary secretion in a dose-dependent manner. Electrical stimulation (6 V, 0.1 ms, 10 Hz and for 30 s) of the chordolingual nerve produced an increase in blood flow (13.3 + 0.9 ml/min, n = 5) comparable to that produced by 3 to 10 nmol of acetylcholine at the peak effect. The muscarinic receptors thus attained, VIP (0.3 to 100 pmol) produced an increase in blood flow which was not significantly different from that in the control (Figure 3 ). The vasodilator responses to nerve stimulation were also unaffected by (-)hyoscyamine (14.3 + 1.2 ml/min against 13.3 + 0.9 ml/min in control, n = 5) (Figure 3 ).
Discussion
In the present experiments, VIP injected into the glandular artery of the submandibular gland of dogs increased blood flow without eliciting salivary secretion. The vasodilator response to VIP was not modified by the blocking action of (-)hyoscyamine, the active moiety of atropine. Secretin injected into the glandular artery also produced vasodilatation without stimulating salivary secretion. The doseblood flow response curves for the two peptides were parallel and the two peptides were able to produce maximum vasodilatation. In other words, the peptides behaved as full agonists and on a molar basis VIP was about 100 times as potent as secretin. (Mutt & Said, 1974) ; VIP has nine amino acids in the same position as in secretin as opposed to six amino acids in the same position as in glucagon. In guinea-pig exocrine pancreatic cells VIP and secretin have been shown to interact with the same receptors but glucagon does not (Klaeveman, Conlon & Gardner, 1975 As shown in the present experiments, the vasodilator potency of VIP in the glandular vascular bed is extremely high, being approximately 100 times that of acetylcholine; it appears to be matched only by that of bradykinin (Satoh et al., 1972; unpublished observations). The high vasodilator potency of bradykinin together with the detection of kallikrein in perfusates of the salivary gland (Hilton & Lewis, 1955) and of the tongue (Hilton & Lewis, 1958) rn chordolingual nerve stimulation led to the supposition that the kallikrein-kinin system mediates the atropine-resistant vasodilatation of these tissues in response to chordolingual nerve stimulation (Hilton & Lewis, 1955; 1958) . However, the failure of bradykinin-potentiating substances to potentiate the vasodilator responses of the salivary gland (Ferreira & Smaje, 1976) and of the tongue (Shimizu & Taira, 1978) of dogs is hard to reconcile with the kallikreinkinin hypothesis (Hilton & Lewis, 1955; 1958) . Alternatively, the high vasodilator potency of VIP and the lack of tachyphylaxis to its vasodilator action tempt us to speculate that VIP may mediate the parasympathetically induced atropine-resistant vasodilatation of the salivary gland and tongue. The demonstration by an immunochemical method of the presence of VIP in nerve fibres in the salivary glands in rats, hogs and man (Bryant et al., 1976 ) may favour our supposition. However, the presence of VIP in nerve fibres in the dog submandibular gland has not been shown as yet. In the study by Bryant et al. (1976) it was not clear whether immunochemically stained VIP nerve fibres were sympathetic or parasympathetic. Said & Rosenberg (1976) have claimed that the distribution of VIP resembles the tissue distribution of noradrenaline. Thus, the consolidation of the VIP hypothesis awaits further study.
